Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era

REFERENCES

• Durandy A. Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future. Transpl Infect Dis 2001;3:104 — 107.
   Google Scholar
• Paya CV, Fung jj, Nalesnik MA, et al. Epstein— Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517— 1525.
   Google Scholar
• Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein—Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:2592— 2598.
   Google Scholar
• Hague T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein—Barr virus-specific cytotoxic T cells. Transplantation 2001;72:1399–1402.
   Google Scholar
• Coiffier B. Monoclonal antibodies combined to chemother-apy for the treatment of patients with lymphoma. Blood Rev 2003;17:25–31.
   Google Scholar
• Cook R, Connors JM, Gascoyne RD, et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999;354:1698–1699.
   Google Scholar
• Habermann TM. Non-Hodgkin's lymphoma: present status and future prospects. Hosp Pract (Off Ed) 1999;34:81— 84.
   Google Scholar
• Walker RC, Marshall WF, Strickler JG, et al. Pretransplanta-tion assessment of the risk of lymphoproliferative disorder. Chin Infect Dis 1995;20:1346–1353.
   Google Scholar
• Leblond V, Dhedin N, Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772–778.
   Google Scholar
• Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplanta-tion 2001;71:1076–1088.
   Google Scholar
• Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphopro-liferative disorders: improved outcome after clinico-patholo-gically tailored treatment. Haematologica 2002;87:67 —77.
   Google Scholar
• Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002;159:9–18.
   Google Scholar
• Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein— Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000;24:375–385.
   Google Scholar
• Oertel S, Anagnostopoulos I, Bechstein WO, et al. Treat-ment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 2000;69:430–432.
   Google Scholar
• McGuirk J, Seropian S, Howe G, et al. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein—Barr virus-associated lymphoproliferation in patients under-going related haplo-identical stem cell transplantation. Bone Marrow Transplant 1999;24:1253–1258.
   Google Scholar
• Zompi S, Tulliez M, Conti F, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol 2000;32: 521 —527.
   Google Scholar
• Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11:113–116.
   Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235— 242.
   Google Scholar
• Habermann T, Weller EA, Morrison VA, et al. Phase III trial of rituximab—CHOP (R— CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observa-tion in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2002;102(11).
   Google Scholar